For Healthcare Professionals: Updates in Liquid Tumors

Watch our videos of experts describing clinical and research advances in leukemia, lymphoma, and other liquid tumors.

Integrated Genetic Profiling in Acute Myelogenous Leukemia

Mutational profiling can improve risk stratification and inform prognostic and therapeutic decisions regarding patients with AML.

Runtime: 03:00 minutes Published: 03/21/2012 - 3:26 PM

Cord Blood Transplantation for Hematologic Malignancies: Improving Access and Outcomes

Cord blood extends access to transplants for the majority of patients.

Runtime: 04:00 minutes Published: 01/10/2012 - 1:51 PM

Developing New Treatments for T Cell Lymphoma

Medical oncologist Steven M. Horwitz discusses the development and impact of three new, widely used therapies for T cell lymphoma: pralatrexate, romidepsin, and brentuximab vedotin.

Runtime: 05:00 minutes Published: 12/27/2011 - 10:48 AM

Role of FDG PET, CT, and Bone Marrow Biopsy (2011 ASH Conference)

Chief of the Lymphoma Service Andrew Zelenetz discusses a retrospective review examining the frequency of FDG avidity across a range of lymphoma histologies.

Runtime: 03:00 minutes Published: 12/10/2011 - 10:47 AM

Pegylated Liposomal Doxirubicin in Cutaneous T Cell Lymphoma (2011 ASH Conference)

Medical oncologist David Straus discusses how sequential bexarotene does not increase response rate in patients with Kaposi’s sarcoma.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:42 AM

Romiplostim in Chemotherapy-Induced Thrombocytopenia (2011 ASH Conference)

Thrombocytopenia is a common effect of cytotoxic chemotherapy regimens in cancer patients, often necessitating reduction or delay in subsequent cycles. While the thrombocytopenia typically resolves with time, a subset of patients with chemotherapy-induced thrombocytopenia (CIT) have prolonged thrombocytopenia, of idiopathic etiology, that interferes with subsequent treatment.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:35 AM

Bexxar/BEAM Versus Rituximab/BEAM and Autologous Stem Cell Transplantation (2011 ASH Conference)

Clinical Director of the Division of Hematologic Oncology Craig Moskowitz discusses a study comparing conditioning regimens followed by autologous stem cell transplantation.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:31 AM

Allogeneic Transplant Following Brentuximab Vedotin Treatment (2011 ASH Conference)

Clinical Director of the Division of Hematologic Oncology Craig Moskowitz discusses positive responses of brentuximab vedotin in patients with Hodgkin lymphoma and systemic ALCL.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:17 AM

Ofatumumab with ICE or DHAP Chemotherapy in B Cell Lymphoma (2011 ASH Conference)

Medical oncologist Matthew Matasar discusses the inclusion of OFA in second-line therapy for aggressive or relapsing B-cell non-Hodgkin’s lymphoma.

Runtime: 02:00 minutes Published: 12/10/2011 - 10:12 AM

WT1-Specific Immune Responses in Multiple Myeloma (2011 ASH Conference)

Medical Director of the Cytotherapy Laboratory Guenther Koehne discusses WT1-specific cellular immune responses in patients with relapsed multiple myeloma and high-risk cytogenetics.

Runtime: 01:00 minutes Published: 12/10/2011 - 10:04 AM

Actinium-225-Lintuzumab in Acute Myeloid Leukemia (2011 ASH Conference)

Medical oncologist Joseph Jurcic discusses a dose-escalation trial reviewing the safety, pharmacology, and biological activity of 225Ac-lintuzumab in AML.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:59 AM

Patterns of Disease Relapse and Progression in Multiple Myeloma (2011 ASH Conference)

Medical oncologist Hani Hassoun reviews a study that examined patterns of post-ASCT relapse.

Runtime: 02:00 minutes Published: 12/10/2011 - 9:51 AM

Predicting Incidence of Dose Limiting Toxicities in Lymphoma Trials (2011 ASH Conference)

Clinical Director of the Lymphoma Outpatient Unit Paul Hamlin discusses relationship between DLT and SAE with increasing age and comorbidities in lymphoma trials.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:43 AM

Late Relapses following ATRA for APL are Uncommon (2011 ASH Conference)

Leader of the Acute Lymphoblastic Leukemia Program Dan Douer discusses a study examining late relapses among APL patients.

Runtime: 02:00 minutes Published: 12/10/2011 - 9:36 AM

ASXL1 Mutations Promote Myeloid Transformation (2011 ASH Conference)

Medical oncologist Omar Abdel-Wahab discusses studies that assessed the functional implications of ASXL1 mutations in the hematopoietic compartment.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:30 AM

SCI-33 Epigenetic Effects of IDH1/IDH2 Mutations (2011 ASH Conference)

Medical oncologist Omar Abdel-Wahab discusses data linking TET2 with the function of cytosine deaminases as a pathway toward DNA demethylation.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:25 AM

Validation of a High-Risk MDS Prognostic Model (2011 ASH Conference)

Medical oncologist Omar Abdel-Wahab discusses a study that validates a lower-risk prognostic scoring system’s ability to identify higher-risk MDS patients.

Runtime: 01:00 minutes Published: 12/10/2011 - 9:04 AM

Arsenic Trioxide as Initial Therapy for Acute Promyelocytic Leukemia

Martin Tallman, a hematologist-oncologist at Memorial Sloan-Kettering, discusses a clinical trial combining arsenic trioxide with all-tansretinoic acid (ATRA) for the treatment of patients with APL.

Runtime: 3:00 minutes Published: 09/14/2011 - 12:00 AM